




In the second half of 2018 this fund was converted into an Australian domiciled iShares ETF, removing the need to complete U.S. tax forms known as "W-8BEN" forms.

INVESTMENT OBJECTIVE

The fund aims to provide investors with the performance of the S&P Global 1200 Healthcare Sector IndexTM, before fees and expenses. The index is designed to measure the performance of global biotechnology, healthcare, medical equipment and pharmaceuticals companies and may include large-, mid- or small-capitalisation stocks.



The chart reflects the performance of a hypothetical investment in the fund of \$AUD10,000 over a specified period in time (M/YY). The performance of the hypothetical investment is based on the actual past performance of the fund over the specified period.

FUND DETAILS

Listing Date 11/03/2009
Inception Date 13/11/2001
Benchmark S&P Global 1200
Healthcare Sector Index

(TM)

Distribution Frequency Semi-Annual Number of Holdings 1
Net Assets 744,464,323 AUD Management Fee* 0.47%
Units Outstanding 7,678,815
See Additional Information note 3.

TOP 10 HOLDINGS (%)

ISHARES GLOBAL HEALTHCARE **ETF TRUS** 99.98 AUD CASH 0.45 USD/AUD 0.00 USD/AUD 0.00 USD/AUD 0.00 USD/AUD 0.00 **USD CASH** -0.43 **TOTAL** 100.00

Holdings are subject to change.


CUMULATIVE AND ANNUALISED PERFORMANCE


	Cumulative			Annualised			
	1 Month	3 Month	YTD	1 Year	3 Year	5 Year	Since Inception
Fund	-3.01%	-2.25%	0.03%	5.73%	11.99%	7.76%	5.45%
Benchmark	-3.01%	-2.43%	-0.06%	5.89%	12.25%	7.92%	5.55%

CALENDAR YEAR PERFORMANCE

	2019	2018	2017	2016	2015
Fund	23.06%	14.00%	11.43%	-5.71%	19.14%
Benchmark	23.50%	14.43%	11.56%	-5.76%	19.27%

The performance figures represent past performance of the fund. Past performance is not a reliable indicator of future performance. Fund performance figures shown are calculated after fund management fees and expenses, and assume reinvestment of distributions. Unless otherwise stated, performance figures are in Australian dollars and performance for periods greater than one year is annualised. Performance is calculated to the last business day of the month. Investment return and principal value of an investment will fluctuate so that an investor's units, when sold or redeemed, may be worth more or less than the original cost. Current performance may be higher or lower than the performance shown. An iShares ETF is not actively managed. You cannot invest directly in an index. See Additional Information note 3.





Top Underlying Holdings (%)	
JOHNSON & JOHNSON	6.45%
UNITEDHEALTH GROUP INC	5.18%
ROCHE HOLDING PAR AG	4.03%
PFIZER INC	3.52%
NOVARTIS AG	3.44%
MERCK & CO INC	3.40%
THERMO FISHER SCIENTIFIC INC	3.34%
ABBOTT LABORATORIES	3.32%
ABBVIE INC	2.68%
DANAHER CORP	2.59%
TOTAL	37.95%

TRADING INFORMATION	
ISIN	AU000000IXJ9
SEDOL	B63QW77
Exchange	ASX - All Markets
Trading Currency	Australian Dollar
IRESS Ticker	IXJ.AXW
Bloomberg Ticker	IXJ

PORTFOLIO CHARACTERISTICS

12m Trailing Yield1.52%Price-Earnings Ratio24.57Price-Book Ratio4.06See Additional Information note 2

Want to learn more?



www.blackrock.com/au/iShares



1300 474 273

Management fees: As stated in the Product Disclosure Statement.

ADDITIONAL INFORMATION 1. Exposure Breakdowns: Allocations are subject to change. Total allocation percentages may not equal 100% due to rounding or omission of holdings of less than 1%. 2. Price-Earnings (P/E) Ratio: A fundamental measure used to determine if an investment is valued appropriately. Each holding's P/E is the latest closing price divided by the latest fiscal year's earnings per share. Negative P/E ratios are excluded from this calculation. Price-Book (P/B) Ratio: A fundamental measure used to determine if an investment is valued appropriately. The book value of a company is a measure of how much a company's assets are worth assuming the company's debts are paid off. Each holding's P/B is the latest closing price divided by the latest fiscal year's book value per share. Negative book values are excluded from this calculation. Distribution Yield: Calculated in AUD by dividing the total distributions paid over a 12 month rolling period by the Fund's closing share price as of the above date. 3. Effective 21 September 2018 this listing was converted into an Australian domiciled iShares ETF. The above Inception and Listing Dates refer to those of the U.S. domiciled listing. Performance figures shown prior to this time are based on the NAV of the U.S. domiciled iShares listing converted from USD to AUD. Performance figures shown after this time are based on the NAV of the Australian domiciled iShares ETF in AUD. The restructure did not impact underlying exposures.

IMPORTANT INFORMATION This material is issued by BlackRock Investment Management (Australia) Limited ABN 13 006 165 975, AFSL 230 523 (BlackRock). It provides general information only and has not been prepared having regard to your objectives, financial situation or needs. Any potential investor should consider their objectives, financial situation, needs and the latest product disclosure statement in deciding whether to acquire, or to continue to hold, an investment in any BlackRock fund. This material is not a securities recommendation nor is it an offer or solicitation with respect to the purchase or sale of any securities in any jurisdiction. BlackRock is the responsible entity and issuer of units in the iShares ETFs referred to in this material. An iShares ETF is not sponsored, endorsed, issued, sold or promoted by the provider of the index which a particular iShares ETF seeks to track. No index provider makes any representation regarding the advisability of investing in the iShares ETFs. Further information on the index providers can be found on BlackRock's website terms and conditions. BlackRock, its officers, employees and agents believe that the information in this material and the sources on which the information is based (which may be sourced from third parties) are correct as at the date of publication. While every care has been taken in the preparation of this material, no warranty of accuracy or reliability for this information. Any investment is subject to investment risk, including delays on the payment of withdrawal proceeds and the loss of income or the principal invested. While any forecasts, estimates and opinions in this material are made on a reasonable basis, actual future results and operations may differ materially from the forecasts, estimates and opinions set out in this material. BlackRock does not guarantee the repayment of capital or the performance of any product or rate of return referred to in this material. Past performance is not a reliable indicator of future performance. No

